Gayashan Tennakoon

Gayashan Tennakoon

Auto-generated profile, based on publicly available information

Gayashan Tennakoon

Cancer Research Program, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2026 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
LALeonard Angka
Leonard Angka
GTGayashan Tennakoon
Gayashan Tennakoon
DCDavid P Cook
David P Cook
AMAndre B Martel
Andre B Martel
RARebecca Craufurd Auer
Rebecca Craufurd Auer
RARebecca C Auer
Rebecca C Auer
Background: Myeloid-derived suppressor cells (MDSCs) have a dominating presence in the postoperative period, mediating the suppression of natural killer (NK) cells and promoting cancer metastases after surgery. However, their phenotype and effects on postoperative cellular immunity remain incompletely understood. This study aims to functionally characterize surgery-induced (sx) MDSCs and identify potential therapeutic strategies to mitigate their immunosuppressive effects. Methods: We used multicolor flow cytometry to characterize sx-MDSCs from n=55 patients with cancer undergoing surgery at various time points. Furthermore, single-cell RNA sequencing was performed on a cohort of patients. Our functional ex vivo sx-MDSC:NK cell suppression assay was used to investigate the activity of sx-MDSCs and to screen a 147 small molecule library to identify sx-MDSC antagonists. Lastly, we used preclinical murine models of postoperative metastases to evaluate the therapeutic potential of the inhibitors identified. Results: Sx-MDSCs significantly expanded after surgery and single-cell RNA sequencing identified signatures resembling immunosuppressive monocytes, including an upregulation of PI3K signaling. These sx-MDSCs also suppressed NK cell activity from patient samples and the small molecule screen identified PI3K-γ inhibitors as potent modulators of sx-MDSC activity. In our murine models, inhibiting PI3K-γ with specific inhibitors reduced postoperative metastases, further corroborating the role of this pathway in sx-MDSC-mediated immune suppression. Conclusions: Our findings highlight the critical role of PI3K-γ signaling in postoperative sx-MDSC-mediated immune suppression. Targeting this pathway with PI3K-γ inhibitors represents a promising therapeutic strategy to prevent NK cell suppression and reduce postoperative metastases.

4 February 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
RARebecca Craufurd Auer
Rebecca Craufurd Auer
GTGayashan Tennakoon
Gayashan Tennakoon
JNJuliana Ng
Juliana Ng
MSMarlena Scaffidi
Marlena Scaffidi
MKMichael Kennedy
Michael Kennedy
RARebecca C Auer
Rebecca C Auer
The majority of data on human Natural Killer (NK) cell phenotype and function has been generated using cryopreserved peripheral blood mononuclear cells (PBMCs). However, cryopreservation can have adverse effects on PBMCs. In contrast, investigating immune cells in whole blood can reduce the time, volume of blood required, and potential artifacts associated with manipulation of the cells. Whole blood collected from healthy donors and cancer patients was processed by three separate protocols that can be used independently or in parallel to assess extracellular receptors, intracellular signaling protein phosphorylation, and intracellular and extracellular cytokine production in human NK cells. To assess extracellular receptor expression, 200 μL of whole blood was incubated with an extracellular staining (ECS) mix and cells were subsequently fixed and RBCs lysed prior to analysis. The phosphorylation status of signaling proteins was assessed in 500 μL of whole blood following co-incubation with interleukin (IL)−2/12 and the ECS mix for 20 minutes prior to cell fixation and RBC lysis and subsequent permeabilization for staining with an intracellular staining (ICS) mix. Cytokine production (IFNγ) was similarly assessed by incubating 1 mL of whole blood with PMA-ionomycin or IL−2/12 prior to incubation with ECS and subsequent ICS antibodies. In addition, plasma was collected from stimulated samples prior to ECS for quantification of secreted IFNγ by ELISA. Results were consistent, despite inherent interpatient variability. Although we did not investigate an exhaustive list of targets, this approach enabled quantification of representative ECS surface markers including activating (NKG2D and DNAM−1) and inhibitory (NKG2D, PD−1, TIGIT, and TIM−3) receptors, cytokine receptors (CD25, CD122, CD132, and CD212) and ICS markers associated with NK cell activation following stimulation, including signaling protein phosphorylation (p-STAT4, p-STAT5, p-p38 MAPK, p-S6K) and IFNγ in both healthy donors and cancer patients. In addition, we compared extracellular receptor expression using whole blood versus cryopreserved PBMCs and observed a significant difference in the expression of almost all receptors. The methods presented permit a relatively rapid parallel assessment of immune cell receptor expression, signaling protein activity, and cytokine production in a minimal volume of whole blood from both healthy donors and cancer patients.